Posts by tag
RAS
Rewriting RAS: A New Targeted Option on the Horizon for Pancreatic Cancer
Metastatic pancreatic cancer remains one of the most treatment-refractory solid tumours in oncology. Despite multiple incremental refinements over the past decade, first-line therapy continues to rely on cytotoxic chemotherapy, most commonly FOLFIRINOX or gemcitabine plus nab-paclitaxel, with limited change in…
Cracking RAS: It took over 30 years to hit this ubiquitous oncogene – was it worth the wait?
RAS oncogenes and their proteins have central roles in almost all cancers, including leukaemias, multiple myelomas, skin cancers and many solid tumours, making the RAS protein family an ideal cancer target. But efforts to develop clinically efficacious drugs to target…
What’s new in lung and colorectal cancer? reports from ESMO 2021
New research findings presented at ESMO 2021 show progress in adjuvant treatment for non-small-cell lung cancer (NSCLC), a novel inhibitor for HER2+ NSCLC patients, and the latest from the FOCUS 4 adaptive, molecularly stratified, umbrella trial platform, set up to…